Refractory angina is chronic chest pain that does not respond to standard treatment, and Rocky Point Stem Cell Therapy approaches it with a combination of conventional symptom management and stem cell therapy.
What Is Refractory Angina?
Refractory angina is a serious and life-threatening condition characterized by chronic chest pain that cannot be relieved. It can cause physical and emotional distress, such as sleep deprivation, depression, and a reduction in everyday activities. Treatment options are available to help manage the symptoms, which can provide patients with some relief and improved quality of life.
Treatments for Refractory Angina
- Outpatient counseling and rehabilitation to help patients cope with the condition.
- Psychotherapy to help reduce the frequency of angina episodes and improve quality of life.
- Various cardiac surgeries, depending on the severity of the condition.
- Transcutaneous electrical nerve stimulation (TENS), a non-invasive therapy used to help reduce the frequency of refractory angina attacks. Used three times a day for an hour, it is intended to help increase tolerance to exercise and reduce the likelihood of future ischemic episodes.
Stem Cell Therapy for Refractory Angina
Research is ongoing into whether refractory angina can be treated with stem cell therapy. Initial studies indicate that hematopoietic stem cells could provide relief from refractory angina, with early results showing improvement in patients given stem cell injections compared to those given placebo injections. A study published in the Journal of the American Heart Association reported promising results for stem cell therapy in treating angina, with relief benefits lasting up to a year and further improved with exercise. While research is still ongoing, these results represent a notable development in the field of cardiovascular health. One independent study reported a 0% mortality rate among patients who received stem cell treatments, compared to a 5.4% mortality rate among those who received placebo treatments within 12 months.
This page is part of our Cardiac use cases. You may also be interested in our pages on Ischemic Cardiomyopathy and Stem Cell Treatment for Congestive Heart Failure, or you can contact our team to discuss your case.

